FIELD: pharmaceutical chemistry.
SUBSTANCE: invention, in particular, relates to prolonged therapeutical form of domestic slow calcium channel blocker, namely ankardin-retard-AZIn (active principle 7,7-ethylenedioxybenzopyran-2,2-dione) in the form of 0.1% solution administered in dose 1 ml in the form of complex with poly(ethylene oxide) 400. Pre-clinical investigations indicated that Ankardin-retard-AZIn was a sufficiently active calcium ion antagonist and, after clinical investigations, it could be applied in medical practice for prevention and treatment of cardiovascular diseases.
EFFECT: extended choice of drugs.
6 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF PREPARING DIUMANCAL-FORTE TABLETS IN DOSE 0,01 G | 2000 |
|
RU2187303C2 |
| AGENT FOR TREATMENT OF PATIENT WITH HEART ISCHEMIC DISEASE | 1998 |
|
RU2155036C2 |
| DERIVATIVES OF 2-H-1-BENZOPYRANE-2-ONE ELICITING ANTI-CALCIUM ACTIVITY | 2003 |
|
RU2242471C1 |
| ANCARDIN-RETARD AS AGENT WITH PROLONGED ANTI-CALCIUM EFFECT | 2002 |
|
RU2219927C1 |
| ANTIARRHYTHMIC DRUG BASED ON HYBRID MOLECULES OF AMLODIPINE WITH (7-METHOXICUMARIN-4-YL)ACETIC ACID | 2018 |
|
RU2678969C1 |
| ANTICOAGULANT AGENT OF INDIRECT ACTION ON BASIS OF DIUMANCAL | 2018 |
|
RU2671983C9 |
| ANTIARRHYTHMIC MEDICATION BASED ON 4-METHYL-7,7'-ETHYLENEDIOXY-2H-1-DIBENZOPYRAN-2,2'-DIONE | 2010 |
|
RU2427368C1 |
| ANTICOAGULANT AGENT OF INDIRECTLY ACTION BASED ON NEW HYBRID MOLECULE OF WARFARIN WITH ESSENTIAL ACID | 2018 |
|
RU2677647C1 |
| IMMUNOMODULATORY AND ANTIVIRAL AGENT BASED ON (2-((COUMARIN-7-YL)OXY)ETHYL) 3-HYDROXY-20(29)-LUPEN-28-OATE | 2018 |
|
RU2686743C1 |
| HYBRID COUMARINS WITH INDIRECT ANTICOAGULANT ACTION | 2018 |
|
RU2672062C1 |
